NAD+ precursor research has taken a new direction in a Science Advances paper published on 6 November 2026. The authors describe (amide-)N-methylnicotinamide, or N-MNA, as a molecule made by certain commensal bacteria and report that it can enter NAD+ metabolism in intestinal cells. The work examines flies, mice and human cells, so it is mechanistic and preclinical rather than evidence for a human treatment. The NAD+ precursor is the focus of this report, and the primary source should guide interpretation. NAD+ research guide.

NAD+ precursor: What is the new NAD+ precursor?

What is the new NAD+ precursor? The paper focuses on an amide form of N-methylnicotinamide. It is structurally different from methylnicotinamide, a degradative metabolite of nicotinamide. The authors report that selected probiotic species produce N-MNA. They also found lower stool N-MNA in people described as having gut dysbiosis and inflammation. That observation is an association, not proof that changing N-MNA would alter disease.

How did the researchers trace it?

How did the researchers trace it? Stable-isotope tracing was used to follow N-MNA after it entered biological systems. The authors report rapid uptake and incorporation into NAD+ redox reactions in intestinal epithelial and non-epithelial cells from fruit fly, mouse and human models. This approach supports a biochemical route, but it does not by itself establish how the molecule would behave in a controlled clinical study.

Which pathway is proposed?

Which pathway is proposed? Genetic and pharmacological experiments suggested that N-MNA is converted to NAD+ through the Preiss-Handler pathway, independently of the better-known salvage pathway. The distinction matters because NAD+ biology contains several connected routes. The study proposes that a microbial metabolite can contribute a methyl group to host cells while entering this cofactor network.

What happened in the gut models?

What happened in the gut models? In Drosophila, the team examined the role of SIRT1, an NAD-consuming enzyme, using cell-type-specific genetic changes. In mice, intestinal stem-cell lineage tracing was used to assess epithelial renewal. The authors report that systemic N-MNA supplementation promoted intestinal stem-cell regeneration and gut epithelial repair in these models. These findings should be read as model-system results, not as a promise of a comparable outcome in people.

Why does this matter for NAD+ studies?

Why does this matter for NAD+ studies? Many NAD+ discussions focus on familiar precursors and on the difficulty of translating biochemical changes into tissue-level effects. This paper adds a microbe-derived candidate to that conversation and links it to intestinal stem-cell biology. It also highlights the importance of tissue, cell type, microbiome state and the route used to measure NAD+ metabolism.

What remains unresolved?

What remains unresolved? The paper does not establish a safe or effective human intervention. It does not show that a laboratory research product is equivalent to the experimental material used by the authors. Questions about dose, delivery, long-term effects, microbiome variation and clinical benefit require separate studies. The finding about lower stool N-MNA in dysbiosis is observational and should not be treated as a diagnostic test.

For laboratory readers, the useful takeaway is narrower: N-MNA is presented as a microbe-derived NAD+ precursor with a proposed biochemical route and preclinical evidence of intestinal repair in flies and mice. The primary paper, rather than a vendor description, should be used for the methods and limitations. Peptra Labs maintains a separate NAD+ research context page for catalogue reference; it is not the study material and this article makes no claim about product performance.

For laboratory readers, the useful takeaway is narrower: N-MNA is presented as a microbe-derived NAD+ precursor with a proposed biochemical route and preclinical evidence of intestinal repair in flies and mice. The primary paper, rather than a vendor description, should be used for the methods and limitations. Peptra Labs maintains a separate NAD+ research context page for catalogue reference; it is not the study material and this article makes no claim about product performance.

For laboratory readers, the useful takeaway is narrower: N-MNA is presented as a microbe-derived NAD+ precursor with a proposed biochemical route and preclinical findings in flies and mice. The primary paper should be used for methods and limits, not a vendor description. See the NAD+ research context, the NAD+ research guide and the RUO glossary entry.

References

  1. Li et al. The (amide-)N-methylnicotinamide is a microbe-derived NAD(+) precursor that drives gut stem cell renewal. Science Advances. 2026. DOI and PubMed.

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.

author-avatar

About Peptra Labs Research

The Peptra Labs research desk follows peptide science: new peer-reviewed studies, EU and US regulatory decisions, and clinical trial results. Every article cites its primary sources. All compounds discussed are for laboratory research use only.